Compare Charles River Laboratories Intl. Inc (CRL) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Global X Uranium ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Global X Uranium ETF trades at $40.87. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| CRL | URA | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $233.60 | $61.81 |
52-Week Low | $145.57 | $36.45 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
URA (Global X Uranium ETF) trades at $40.72, down 5.24% over 24 hours amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though RSI indicators suggest potential oversold conditions. Recent news highlights uranium's strategic positioning at the intersection of AI power demand and nuclear energy revival, with the fund holding $6.29 billion in assets across 56 uranium-related companies.
The ETF's outlook balances near-term technical weakness against strong secular tailwinds from AI-driven electricity demand and nuclear policy support. Key risks include uranium price volatility and competition from pure-miner alternatives, while the current oversold technical condition may present entry opportunities for long-term investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
